Persistent and pathogen-specific infection risk during long-term survivorship after CD19 chimeric antigen receptor T-cell therapy: an Australian multicentre cohort study
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 chimeric antigen receptor T-cell therapy: an Australian multicentre cohort study. // Clinical Microbiology and Infection. – URL: https://www.sciencedirect.com/science/article/pii/S1198743X26003319?dgcid=rss_sd_all
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 chimeric antigen receptor T-cell therapy: an Australian multicentre cohort study. Clinical Microbiology and Infection. https://www.sciencedirect.com/science/article/pii/S1198743X26003319?dgcid=rss_sd_all
“Persistent and pathogen-specific infection risk during long-term survivorship after CD19 chimeric antigen receptor T-cell therapy: an Australian multicentre cohort study.” Clinical Microbiology and Infection.
@article{article41108,
title = {Persistent and pathogen-specific infection risk during long-term survivorship after CD19 chimeric antigen receptor T-cell therapy: an Australian multicentre cohort study},
journal = {Clinical Microbiology and Infection},
url = {https://www.sciencedirect.com/science/article/pii/S1198743X26003319?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...